ArticleFrontiers in immunology2026
Stereotactic versus whole-brain radiotherapy combined with immunotherapy in driver gene-negative NSCLC with brain metastases: a real-world IPTW analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Concurrent Stereotactic Radiotherapy and Immune Checkpoint Inhibitors for Multiple Brain Metastases in Non-Small Cell Lung Cancer - A Multi-Center Retrospective Analysis.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain metastases (BMs) are a common and prognostically unfavorable complication of non-small cell lung cancer (NSCLC). Although the combination of immune checkpoint inhibitors (ICIs) with radiotherapy has shown potential in the treatment of BMs, there is a lack of comparative studies specifically contrasting whole-brain radiotherapy (WBRT) versus stereotactic radiotherapy (SRT), each combined with immunotherapy. This study aimed to systematically evaluate the efficacy and safety of WBRT plus immunotherapy (WBRT+I) versus SRT plus immunotherapy (SRT+I) in patients with driver-gene-negative NSCLC accompanied by BMs. Methods: This single-center, real-world retrospective cohort study enrolled patients with driver gene-negative NSCLC and BMs who received their first course of intracranial radiotherapy at Chongqing University Cancer Hospital between January 2018 and June 2024. Inverse Probability of Treatment Weighting (IPTW) was applied to balance baseline variables between the WBRT+I and SRT+I groups. Survival outcomes were evaluated using Kaplan-Meier analysis and Cox regression. The primary endpoints were overall survival (OS) and intracranial progression-free survival (iPFS). Secondary endpoints included the intracranial objective response rate (iORR), intracranial disease control rate (iDCR), and safety profile. Results: In this real-world cohort of 158 patients with driver gene-negative NSCLC with BMs, SRT+I demonstrated superior survival outcomes compared to WBRT+I. After IPTW adjustment, SRT+I was associated with significantly prolonged median overall survival (29.3 vs. 19.9 months, Conclusion: In driver-gene-negative NSCLC patients with BMs, SRT+I demonstrates superior survival and intracranial disease control compared to WBRT+I, particularly in those with limited BMs. These findings provide high-level evidence for optimizing individualized clinical strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.